A Phase I study of TSU-68 in combination with Carboplatin and Paclitaxel in patients with Advanced Non-Small Cell Lung Cancer
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Orantinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
Most Recent Events
- 01 Jun 2016 New trial record